Testing a promising MS drug in young patients

NCT ID NCT04075266

Ongoing Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

Summary

This study is testing the safety and determining the right dose of the drug ocrelizumab for children and teenagers (ages 10-18) with relapsing-remitting multiple sclerosis (MS). It involves a small group of 23 participants and will last for two years. The main goal is to gather information to plan a larger, more definitive study in the future.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

AOU Policlinico V. Emanuele - P.O G. Rodolico

Catania, Sicily, 95123, Italy
Azienda Ospedaliera Sant'Andrea

Rome, Lazio, 00189, Italy
Boston Childrens Hospital

Boston, Massachusetts, 02115, United States
Childrens National Health Center

Washington D.C., District of Columbia, 20010, United States
Cleveland Clinic

Cleveland, Ohio, 44195, United States
Dzieci?cy Szpital Kliniczny im. Józefa Polikarpa Brudzi?skiego

Warsaw, 02-091, Poland
Instytut Pomnik Centrum Zdrowia Dziecka

Warsaw, 04-730, Poland
Ospedale Pediatrico Bambino Gesù

Rome, Lazio, 00165, Italy
University of Colorado Denver Childrens Hospital Rocky Mountain MS Center

Aurora, Colorado, 80045, United States
Uniwersytecki Szpital Kliniczny w Poznaniu

Późna, 60-355, Poland
Uniwersyteckie Centrum Kliniczne

Gda?sk, 80-952, Poland
Washington Universtiy school of Medicine

St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.

MULTIPLE SCLEROSIS